Trial Profile

A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Petrelintide (Primary)
Indications Obesity
Focus Adverse reactions; Therapeutic Use
Acronyms ZUPREME-1
Sponsors Zealand Pharma

Most Recent Events

23 Mar 2026 Status changed from active, no longer recruiting to completed.
06 Mar 2026 According to a Roche media release, the final ZUPREME-1 data, along with a 9-week safety follow-up, will be presented at an upcoming medical congress and will inform the optimal Phase III designs.
06 Mar 2026 Results presented in Roche Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com